Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
Debra Van Egeren, Alexander Novokhodko, Madison Stoddard, et al.
PLoS ONE (2021) Vol. 16, Iss. 4, pp. e0250780-e0250780
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
Global landscape of SARS-CoV-2 mutations and conserved regions
Mohammad Hadi Abbasian, Mohammadamin Mahmanzar, Karim Rahimian, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 61
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Predicting the zoonotic capacity of mammals to transmit SARS-CoV-2
Ilya R. Fischhoff, Adrian A. Castellanos, João Rodrigues, et al.
Proceedings of the Royal Society B Biological Sciences (2021) Vol. 288, Iss. 1963
Open Access | Times Cited: 76
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
John Charles Rotondo, Fernanda Martini, Martina Maritati, et al.
Viruses (2021) Vol. 13, Iss. 9, pp. 1687-1687
Open Access | Times Cited: 75
Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves
Simon Bauer, Sebastián Contreras, Jonas Dehning, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 9, pp. e1009288-e1009288
Open Access | Times Cited: 66
A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection
David A. Jamison, S Narayanan, Nídia S. Trovão, et al.
European Journal of Human Genetics (2022) Vol. 30, Iss. 8, pp. 889-898
Open Access | Times Cited: 65
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Hejun Liu, Meng Yuan, Deli Huang, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 806-818.e6
Open Access | Times Cited: 63
COVID-19 Vaccines: An Overview of Different Platforms
D.А. Kudlаy, Andrey Svistunov
Bioengineering (2022) Vol. 9, Iss. 2, pp. 72-72
Open Access | Times Cited: 61
The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
Shilei Zhang, Lulan Wang, Genhong Cheng
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1869-1884
Open Access | Times Cited: 59
Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19
Arpana Parihar, Zannatul Ferdous Sonia, Farjana Akter, et al.
Computers in Biology and Medicine (2022) Vol. 145, pp. 105468-105468
Open Access | Times Cited: 53
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
Analysis of SARS-CoV-2 genome evolutionary patterns
Shubhangi Gupta, Deepanshu Gupta, Sonika Bhatnagar
Microbiology Spectrum (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 6
Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad, et al.
JCI Insight (2022) Vol. 7, Iss. 10
Open Access | Times Cited: 26
Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2
Debra Van Egeren, Madison Stoddard, Laura F. White, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 853-853
Open Access | Times Cited: 14
Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences
Shalakha Hegde, Zhichao Tang, Junxing Zhao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 30
Predicting the zoonotic capacity of mammals to transmit SARS-CoV-2
Ilya R. Fischhoff, Adrian A. Castellanos, João Rodrigues, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 29
Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma, et al.
GeroScience (2022) Vol. 44, Iss. 5, pp. 2371-2392
Open Access | Times Cited: 21
The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Qiuli Chen, Jiawei Zhang, Peter Wang, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105044-105044
Open Access | Times Cited: 21
Omicron mutations increase interdomain interactions and reduce epitope exposure in the SARS-CoV-2 spike
Miłosz Wieczór, Phu K. Tang, Modesto Orozco, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105981-105981
Open Access | Times Cited: 11
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
Tharmala Tharmalingam, Xiaobing Han, Ashley Wozniak, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 2
Open Access | Times Cited: 23
Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure
Debra Van Egeren, Alexander Novokhodko, Madison Stoddard, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 22
The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus
Shaza S. Issa, С. В. Сокорнова, Roman R. Zhidkin, et al.
Plants (2022) Vol. 11, Iss. 14, pp. 1862-1862
Open Access | Times Cited: 15
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design
Yashavantha L. Vishweshwaraiah, Brianna Hnath, Brendan Rackley, et al.
Advanced Functional Materials (2022) Vol. 32, Iss. 49
Open Access | Times Cited: 13
Plantaricin NC8 αβ rapidly and efficiently inhibits flaviviruses and SARS-CoV-2 by disrupting their envelopes
Abubakr A. M. Omer, Jorma Hinkula, Pham-Tue-Hung Tran, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0278419-e0278419
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top